Исследования выполнены при поддержки гранта Российского научного фонда (№19-15-00110).
Литература
1. Lee R.G., Crosby J., Baker B.F., Graham M.J., Crooke R.M. Antisense Technology: An Emerging Disease Therapeutics. Journal of Cardiovascular Translational Research. 2013;(6):969-980.
2. Zborovskaya I.B., Komel'kov A.V. MicroRNA-155-5p in pathogenesis of cancer. Advances in Molecular Oncology. 2017;4(3):27-36.
3. Esau C.C., Monia B.P. Therapeutic potential for microRNAs. Advanced Drug Delivery Reviews. 2007;59 (2-3):101-114.
4. Palkina N.V., Komina A.V., Aksenenko M.B., Ruksha T.G. MicroRNA 204-5p decreases proliferation/viability and the ability to form colonies in melanoma cells. Journal of Investigative Dermatology. 2017; 137(10): 291.
5. Peinado H., Zhang H., Matei I.R., Costa-Silva B., Hoshino A., Rodrigues G., Psaila B., Kaplan R.N., Bromberg J.F., Kang Y., Bissell M.J., Cox T.R., Giaccia A.J., Erler J.T., Hiratsuka S., Ghajar C.M., Lyden D. Pre-metastatic niches: organ-specific homes for metastases. Nature Reviews Cancer. 2017;17(5):302-317.
6. Lu P, Weaver V.M., Werbcorresponding Z. The extracellular matrix: A dynamic niche in cancer progression. Journal of Cell Biology. 2012;196(4):395-406.
7. Ozbek S, Balasubramanian PG, Chiquet-Ehrismann R, Tucker RP, Adams JC. The evolution of extracellular matrix. Molecular and Cellular Biology. 2010;21(14):4300-4305.
8. Xiong TF, Pan FQ, Li D. Expression and clinical significance of S100 family genes in patients with melanoma. Melanoma Research. 2019;29(1):23-29.
9. Sanna L, Marchesi I, Melone MAB, Bagella L. The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma. Journal of Cellular Physiology. 2018;233(9):6508-6517.
10. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutation Research. 2008;627(1-2):21-29.
11. Sun R, Shen J, Gao Y, Zhou Y, Yu Z, Hornicek F, Kan Q, Duan Z. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential. Oncotarget. 2016;7(25):38333-38346.
12. Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE. In Vivo ERK1/2 Reporter Predictively
Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. Molecular Cancer Therapeutics. 2019;18(9):1637-1648.
13. Fu H, Cheng L, Sa R, Jin Y, Chen L. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAFV600E by synergistically decreasing global trimethylation of H3K27. Journal of Cellular and Molecular Medicine. 2020;24(6):3336-3345.